Neuberger Berman Group
ACAD icon

Neuberger Berman Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Neuberger Berman Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-470,900
Closed -$25.2M – 1759
2020
Q4 		$25.2M Buy
470,900
+92,800
+25% +$4.61M 0.03% 574
2020
Q3 		$15.6M Buy
378,100
+160,000
+73% +$6.91M 0.02% 636
2020
Q2 		$10.6M Buy
218,100
+165,000
+311% +$7.92M 0.01% 703
2020
Q1 		$2.24M Buy
53,100
+13,000
+32% +$536K ﹤0.01% 922
2019
Q4 		$1.72M Buy
40,100
+13,700
+52% +$596K ﹤0.01% 1059
2019
Q3 		$950K Buy
26,400
+2,800
+12% +$84.9K ﹤0.01% 1162
2019
Q2 		$631K Buy
23,600
+10,600
+82% +$271K ﹤0.01% 1247
2019
Q1 		$349K Buy
+13,000
New +$304K ﹤0.01% 1336
2017
Q3 		– Sell
-62,664
Closed -$1.75M – 1596
2017
Q2 		$1.75M Buy
62,664
+29,326
+88% +$874K ﹤0.01% 1030
2017
Q1 		$1.15M Buy
+33,338
New +$1.18M ﹤0.01% 1120
2015
Q2 		– Sell
-391,600
Closed -$12.8M – 1553
2015
Q1 		$12.8M Buy
391,600
+365,800
+1,418% +$12.6M 0.01% 791
2014
Q4 		$819K Buy
+25,800
New +$732K ﹤0.01% 1259
2014
Q3 		– Sell
-16,325
Closed -$369K – 1640
2014
Q2 		$369K Sell
16,325
-27,625
-63% -$577K ﹤0.01% 1446
2014
Q1 		$1.07M Sell
43,950
-7,985
-15% -$202K ﹤0.01% 1203
2013
Q4 		$1.3M Buy
+51,935
New +$1.23M ﹤0.01% 1153

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Neuberger Berman Group's ACAD Position: Q1 2021 in Review

Neuberger Berman Group sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 470,900 shares — an estimated $25.2M sold.

Neuberger Berman Group first reported a position in ACAD in Q4 2013 and held it in 15 quarters. The position peaked at $25.2M in Q4 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

  • Neuberger Berman Group reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Neuberger Berman Group sold 470,900 Acadia Pharmaceuticals shares in Q1 2021, an estimated $25.2M.
  • Neuberger Berman Group first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 15 quarters.
  • Neuberger Berman Group's Acadia Pharmaceuticals position peaked at $25.2M in Q4 2020.
  • 272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Neuberger Berman Group's 13F filing for Q1 2021, filed 13 May 2021.